eucast: Clinical breakpoints and dosing of antibiotics
In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the Enterobacteriaceae and Pseudomonas aeruginosa, daptomycin breakpoints for Enterococcus spp
Antimicrobial agents that may warrant testing and reporting by clinician request if antimicrobial agents – MIC and DD breakpoints for Enterobacterales and Pseudomonas aeruginosa –standards M02, M07, and M11
In this scenario, the first hospital used outdated breakpoints that classified the organism as susceptible to a particular antibiotic when it was not
aeruginosa are ≤0
The Clinical and Laboratory Standards Institute (CLSI) revised the fluoroquinolone MIC breakpoints for Enterobacterales in 2019, based on
There are notable differences in recognized S maltophilia breakpoints between the CLSI and the FDA
Clinical & Laboratory Standards Institute: CLSI Guidelines Effective May 29, 2019, Legacy Laboratory Services will change the breakpoints for reporting Ciprofloxacin and Levofloxacin for Enterobacteriaceae and Pseudomonas
Find local businesses, view maps and get driving directions in Google Maps
Effective May 29, 2019, Legacy Laboratory Services will change the breakpoints for reporting Ciprofloxacin and Levofloxacin for Enterobacteriaceae and Pseudomonas aeruginosa
Streptococcus pneumoniae b-hemolytic Streptococcus spp
In 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the Enterobacteriaceae and Pseudomonas aeruginosa, daptomycin breakpoints for Enterococcus spp
Dilution Methods
Clinical and Laboratory Standards Institute, Wayne, PA
If the commercial system does not extend below 4µg/mL How to approach instances where there are no clinical breakpoints
Objectives: Breakpoints provided by European Committee on Antimicrobial Susceptibility Testing (EUCAST) are now being used in many countries
• Azithromycin: MIC breakpoints for N
The breakpoint for susceptible is based on a dosage regimen of 600 mg administered every 12 h
a
2 to 100 %, 94
3 % (3/29) for levofloxacin
3 Volume 8, Issue 1, June 2023 CLSI M100-Ed33: Updated Aminoglycoside Breakpoints for Enterobacterales and Pseudomonas aeruginosa (Continued) An important change with the updated breakpoints is the elimination of gentamicin as a suggested treatment option for P
INTRODUCTION
a Aztreonam Ceftazidime Chloramphenicolc Gentamicin (high-level resistance testing only) Ciprofloxacin or levofloxacin Moxifloxacin Streptomycin (high-level Ceftaroline resistance testing only) Chloramphenicolb,c Tetracyclineq Dalbavancini,s Gentamicint Oritavancini,s Purpose of Review This review outlines the process of setting and revising Clinical and Laboratory Standards Institute (CLSI) breakpoints and summarizes breakpoints approved in 2023
coli ATCC® 13353 – Klebsiella pneumoniae ATCC® BAA-1705 – K
9%, respectively, by CLSI criteria), while resistance rates were <1% for linezolid, daptomycin, and vancomycin (Table 2)
1,2 This agent is no longer available